Next Article in Journal
Right Ventricle Metastasis of Pulmonary Sarcomatoid Carcinoma
Previous Article in Journal
Author’s Reply
 
 
Cardiovascular Medicine is published by MDPI from Volume 28 Issue 1 (2025). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Editores Medicorum Helveticorum (EMH).
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

LAA Occluders for All Patients with Atrial Fibrillation - An Overreaching Statement

by
Michael Kühne
*,
Tobias Reichlin
,
Beat Schaer
,
Stefan Osswald
and
Christian Sticherling
University Hospital Basel, Basel, Switzerland
*
Author to whom correspondence should be addressed.
Cardiovasc. Med. 2017, 20(3), 467; https://doi.org/10.4414/cvm.2017.00467 (registering DOI)
Submission received: 15 December 2016 / Revised: 15 January 2017 / Accepted: 15 February 2017 / Published: 15 March 2017
With great interest we read the article by Ghenzi et al. on “The evolving role of left atrial appendage (LAA) occlusion” published in the November 16th issue of Cardiovascular Medicine. However, the three conclusions drawn by the authors warrant some comments.
The conclusion that “LAA occlusion should be considered a first-line therapy for stroke prevention and discussed as a treatment option with all patients with atrial fibrillation” is daring. Based on the 2016 ESC Guidelines for the management of atrial fibrillation, LAA occlusion is currently considered a IIb (level of evidence C) indication in patients with atrial fibrillation, an indication for oral anticoagulation (OAC) and at the same time a clear contraindication for OAC. The data presented by the authors shows that in the patients undergoing LAA occlusion there were reasons for withholding OAC in the vast majority of cases, with a fair share (42.5%) of the patients having previous relevant bleeding. This means that the authors actually appear to use LAA occlusion in patients with an absolute or relative contraindication to OAC. Therefore, the statement that LAA occlusion should be considered a first-line therapy is not only not supported by current guidelines but also not backed by the presented data.
The conclusion that “LAA occlusion could be performed with a low complication rate” is at least debatable and depends on the “willingness-to-accept complications” threshold discussed with the patient. A major complication rate of 4.9% may be acceptable if there are no alternatives (i.e., in patients with a clear contraindication to OAC) but may be considered high when starting to use LAA occlusion as first-line therapy.
Finally, the conclusion that “LAA occlusion can be performed with high success rate” is supported by the presented data with a reported procedural success rate of 98.4%. A high procedural success rate may rightfully lower the threshold for performing a procedure, but, as Lord Henry Cohen of Birkenhead (1900–1977) once said: “The feasibility of an operation is not the best indication for its performance.”

Share and Cite

MDPI and ACS Style

Kühne, M.; Reichlin, T.; Schaer, B.; Osswald, S.; Sticherling, C. LAA Occluders for All Patients with Atrial Fibrillation - An Overreaching Statement. Cardiovasc. Med. 2017, 20, 467. https://doi.org/10.4414/cvm.2017.00467

AMA Style

Kühne M, Reichlin T, Schaer B, Osswald S, Sticherling C. LAA Occluders for All Patients with Atrial Fibrillation - An Overreaching Statement. Cardiovascular Medicine. 2017; 20(3):467. https://doi.org/10.4414/cvm.2017.00467

Chicago/Turabian Style

Kühne, Michael, Tobias Reichlin, Beat Schaer, Stefan Osswald, and Christian Sticherling. 2017. "LAA Occluders for All Patients with Atrial Fibrillation - An Overreaching Statement" Cardiovascular Medicine 20, no. 3: 467. https://doi.org/10.4414/cvm.2017.00467

APA Style

Kühne, M., Reichlin, T., Schaer, B., Osswald, S., & Sticherling, C. (2017). LAA Occluders for All Patients with Atrial Fibrillation - An Overreaching Statement. Cardiovascular Medicine, 20(3), 467. https://doi.org/10.4414/cvm.2017.00467

Article Metrics

Back to TopTop